Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced its bitXbio ...

Evofem Biosciences, the buzzy but controversial women’s health startup that spent the past year trying to stay afloat, has finally found a buyer.

Evofem Biosciences (NASDAQ:EVFM) just reported results for the second quarter of 2024. The company did not report any EPS for the quarter. The company reported revenue of $4.16 million ...

Even though Evofem Biosciences shares are still up sharply from their pre- Dobbs v. Jackson Women’s Health Organization ruling levels, the stock has pulled back sharply from its post-decision peak.

Evofem Biosciences is making top-to-bottom cuts in a bid to slash its costs. Months after laying off 39 people, the women’s health biotech has pushed more employees, including its chief ...

Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the third quarter and nine-month period ended September 30, 2024 ...

Evofem acquired global rights to the product in July 2024 and relaunched SOLOSEC in the U.S. in November 2024 with its women's health-focused commercial team.

Tuesday, Evofem agreed to sell itself to Richmond-based biotech Aditxt for around $100 million, the companies said in a joint release.

Evofem's Phexxi works with pH levels to prevent pregnancies without the use of hormones.

Aditxt has signed a market development collaboration agreement with Evofem Biosciences to commercialise the former’s blood-based diagnostic test for endometriosis. As part of the agreement, the ...